Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • ShortsalgSe hvilke børsnoterede selskaber der har offentliggjorte korte positioner
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Transskriptioner

Læs transskriptioner af webcasts og audiocasts

Transskriptioner

Læs transskriptioner af webcasts og audiocasts

Alle regioner
Danmark
Sverige
Finland
Norge
Seneste
Populært
Fulgt

Calliditas Therapeutics, Audiocast with teleconference, Q1'24

Af Inderes23.5.2024, 12.30
Calliditas Therapeutics

Ansvarsfraskrivelse: Dette er en maskin­genereret transskription og kan indeholde unøjagtigheder.

Renee Aguilar Alexander
00:01 - 05:36

Much appreciated, and welcome to this Q1 2024 report from Calliditas Therapeutics. My name is Renée Aguilar Alexander. I'm the CEO of the company, and I'm joined today by Fredrik Johansson, our chief financial officer, Richard Philipson, our chief medical officer, and Maria Törnsén, our president of North America. Next page please. I'd like to draw your attention to the disclaimer notice, which covers forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. And I refer to public filings, including those containing risk factors. Next page please. So I'd like to take you through some of our Q1 highlights, which included the appointment of Maria Törnsén as president of North America, who brings over ten years of rare disease experience to Calliditas, including multiple product launches both in the US and ex-US. Following our full approval in December last year, we were able to roll out new marketing materials to a fully trained field team in February, introducing the new indication of reduction of loss of kidney function to nephrologists in the US. In February, we also announced that the US PTO had issued a new patent covering TARPEYO with expiration in 2043. In March, we could also announce that the FDA had granted seven years of orphan exclusivity for the new indication, which expires in December of 2030. Finally, we also secured approval in Singapore of NEFEGAN, which will be marketed as such. Next page please. In terms of commercial highlights for the quarter. This I want to clarify, from a commercial perspective, this quarter was another record quarter in terms of enrollments, with 705 new enrollments, reflecting a 27% increase over the previous quarter, in which we saw a 51% increase. This continued strong demand is very encouraging, and we continue to see strong demand for the product in the market. As expected, we saw somewhat of a lighter quarter from a revenue perspective due to the typical re-verification process. But this quarter also saw something quite unexpected in the form of a cyberattack on Change Health, one of the three providers of claims processing in the US. We use one specialty pharmacy management company, Biologics, which exclusively uses Change Health, which, due to the delays in processing, due to this cyberattack, led to a negative impact on the quarter of approximately $4.7 million, resulting in net product revenues for the quarter of $26.8 million. We do not expect this to have an impact on our annual revenues if these revenues are not lost but merely pushed out in time, which is also borne out by the strong start to Q2, reflected by net product revenues quarter to date of approximately $25.5 million, with an additional five weeks to go in the quarter. The team has during the quarter undertaken a very substantial number of committee meetings, and we're starting to see some plans update their rules. But our expectations remain that the majority of plans will update their rules in the June-July time frame. We're also hopeful that the EMA will review and make recommendations regarding a potential full approval of Kinpeygo at their next meeting, and in the period post a quarter. We also were excited to see the commercial launch in China by our partner, Everest Medicines. Next page please. Other post period events. So we did have a positive readout of our phase two proof of concept trial in head and neck cancer. Which Richard will give you a little bit more information on. But we saw statistically significant benefits in progression-free survival as well as overall survival. There's also an R&D day that's been scheduled for May 30th to provide some additional information around that on setanaxib. We also had supportive open label extension data, which we presented at the International Society of Nephrology. There were several abstracts presented at the International Society of Nephrology World Congress, which again, Richard will cover shortly. There was also a new patent in the form of a notice of allowance that was received for setanaxib in the area of cancer. And as I already mentioned, there was the commercial launch in China by Everest Medicines. Next page please. So in conclusion to this section, I just want to highlight that we are very excited about what 2024 will bring following the successful start in Q1. That includes the potential full approval of Kinpeygo in Europe, the commercial build out in China, with the potential for an agreement to be included in negotiations related to national reimbursement already this year, potentially the readout of certain active data from the phase two trial in PBC, which we expect to be able to share with you in Q3. The readout from a phase two investigator-led study in IPF, which we're hoping to be able to share with you in Q4. Reimbursement decisions are expected for additional countries in Europe by our partner working with that data. And then we're also hopeful that we will see the start of a phase three study in Japan with Kinpeygo and by our partner, Viatris. And obviously, we're certainly looking forward to continued strong growth of TARPEYO in the US market. And with that, I'm going to hand over to Richard Philipson.

Richard Philipson
05:36 - 12:07

Thank you very much Renee. So next slide, I'd like to start by talking briefly about our recent conference attendance. Next slide. We're delighted to have had a strong presence at the World Congress of Nephrology, a conference organized by the International Society of Nephrology, which was held in Buenos Aires from the 13th to the 16th of April. This year, we presented four posters and also held a sponsored symposium where Doctors Richard Lafayette, Laura Mariani, and Heather Richter presented and discussed the evolving landscape of eGFR and proteinuria. Surrogate markers in chronic kidney disease (CKD). We very much valued the opportunity to meet with nephrologists from the US, and also from many other countries where we were able to talk about IgA nephropathy and hear about their experiences in managing the condition. I'd like to highlight some of the data and analyses that we presented at this conference. Next slide. One of the important observations that we made in the secondary analysis of the phase three trial was that the time to 30% reduction in eGFR, or kidney failure, was significantly delayed in patients treated with TARPEYO. This analysis was presented in a poster at WCN, and is also illustrated in a figure on the right of this slide, demonstrating a 55% reduction in the risk of an event in patients treated with TARPEYO compared to placebo-treated patients, which was statistically significant with a p-value of 0.0014. It's also noteworthy that this treatment effect was consistent irrespective of the baseline UPCR category, with hazard ratios of 0.51 and 0.42 for the below and above 1.5 g/g UPCR categories. Other posters presented additional analyses from the trial. These posters included a subgroup analysis indicating that TARPEYO was efficacious and well tolerated, irrespective of white or Asian race. A poster described the beneficial effects of TARPEYO on eGFR slope in patients with lower levels of baseline proteinuria. And finally, a poster describing quality of life outcomes. Next slide. So I'd now like to move on and talk about the recently announced results of the company's phase two proof of concept study in squamous cell carcinoma of the head and neck. Next slide. As a brief reminder, this was a randomized, placebo-controlled, double-blind, phase two study investigating the effects of setanaxib 800mg twice daily in conjunction with pembrolizumab 200mg IV, administered every three weeks. Patients with recurrent or metastatic squamous cell carcinoma of the head and neck, and with moderate or high levels of cancer-associated fibroblasts in the tumor, were randomized to receive setanaxib or placebo on top of standard of care, pembrolizumab. The tumor biopsy was taken prior to randomization and again approximately nine weeks after the start of treatment. Treatment continued until disease progression. For brevity, I'll subsequently describe the treatment groups as setanaxib or placebo. But please remember that these randomized treatments were both given in addition to pembrolizumab. Next slide. The study was conducted at 37 sites in seven countries. The last patient was randomized on the 25th of October, 2023. The data collected until all randomized patients had at least 15 weeks of follow-up. The primary analysis comprised 55 randomized patients and included 38 progression events, which was in line with our target for the statistical analysis. The treatment groups were well balanced at baseline and importantly, no patients were excluded from any of the analysis sets, nor were there any important protocol deviations that were considered likely to impact efficacy. Next slide. We observed statistically significant improvements in progression-free survival and overall survival. Median progression-free survival was five months in certain actively treated patients, versus 2.9 months in placebo-treated patients. The hazard ratio for this outcome was 0.58. In other words, patients treated with certain drugs had a 42% lower risk of experiencing disease progression at any time during the study at six months. 92% of patients treated with the drug were alive, compared to 68% placebo-treated patients. The respective percentages were 88% and 58% at nine months, and the hazard ratio for this outcome was 0.45. In other words, patients treated with certain drugs had a 55% lower risk of death at any time during the study. We also saw a higher percentage of patients actively treated achieving a best response of at least stable disease. 70% of patients actively treated showed a best response of at least stable disease, compared to 52% of placebo-treated patients, and the responses in actively treated patients appeared to be more durable. It was very pleasing to see a corresponding increase in CD8 positive T-cells in tumor tissue in response to active treatment, which supports the mechanism of action assessment in solid tumors and indicates an increase in the immunological activity of the tumor. There was no significant difference in the primary endpoint of best percentage change from baseline in tumor size. From a safety point of view, the tolerability of active treatment when given with pembrolizumab was generally good, but no new safety signals were identified. Next slide. So in summary, we saw statistically significant improvements in progression-free survival and overall survival with more durable responses in treated patients. There was an increase in intratumoral CD8 positive T-cells in actively treated patients, which is in line with the mechanism of action of treatment, and indicates an increase in the immunological activity of the tumor. Finally, the active treatment was generally well tolerated when given with pembrolizumab, and there were no new safety signals. So I'd like to now hand over to Maureen Thompson.

Renee Aguilar Alexander
12:09 - 12:09

Thank you very much.

Maria Törnsén
12:09 - 16:10

Much appreciated, Richard. Next slide please. As you recall, in Q4 2023, we had our strongest quarter since launch with 555 enrollment forms. And in the first quarter of 2024, we continue to see a very strong demand for the product, with 705 enrollment forms received by our patient services hub, RPO touchpoints. During this quarter, we also had 354 new prescribers, which is another record since launch. And we now have close to 2000 healthcare providers who have prescribed our RPO. We believe that the strong demand we are seeing is an early sign of the impact of our full approval. Our new label, with the removal of the UPCR criteria and physicians recognizing the impact RPO has on reducing the loss of kidney function. Our total sales, which are in Q1, was $26.8 million. As Renee mentioned earlier, Q1 was impacted by seasonal changes due to the open enrollment period in the US as well as the cyberattack on Change Health. And this does not impact our 2024 guidance. As you can see from our estimated quarter two sales to date, we've seen a very strong revenue in the first eight weeks of the quarter, with approximately $25.5 million of net sales. Next slide, please. In the first quarter, we launched the full approval of TARPEYO with multiple commercial and medical activities. As a reminder, TARPEYO is the first and only product approved by the FDA to reduce the loss of kidney function for patients at risk of progression. Our field teams are trained on our new label and are promoting it to healthcare professionals. We have also launched various new patient educational programs, materials, and market research initiatives. We know that patients appreciate TARPEYO's nine-month treatment course with no REMS requirement, as it provides them with the freedom to complete a course and see the long-term benefits. Our medical team has been engaged in multiple scientific exchanges and participated at congresses. At WCN in April, we had presentations highlighting the eGFR results and impact on quality of life experienced by patients in the clinical trial. And finally, our Market Access team has been busy engaging with payers, educating them on our new label, the inclusion of the eGFR data, and removal of the UPCR criteria. Next slide, please. We're very excited about the opportunity ahead of us. We see a very strong demand for Kinpeygo, both from existing and new prescribers who recognize its positioning as a disease-modifying therapy in IgAN. Our focus is on continuing our promotional efforts with our expanded field team and driving scientific exchange at large conferences. We're eagerly awaiting the update of the new guidelines and estimates. They will be published in the second half of 2024. These guidelines have the potential to broaden the definition of the At-Risk population, and also support the use of Kinpeygo as the only fully approved drug with an impact on eGFR. As mentioned earlier, we continue to focus on engaging with US payers to ensure that their policies reflect the new label. We have already seen one of the largest payers in the US, UnitedHealthcare, update their policy in May, and we are anticipating that the largest payers will update their policies mid-2024. This should facilitate access for patients and reduce market access barriers. And with that, I will hand it over to our CFO, Fredrik Johansson, to talk about our financial projections.

Fredrik Johansson
16:11 - 19:58

Thank you, Maria. Next slide, please. I will now present to you the financial overview for the first quarter. As always, the numbers presented to you are in millions unless otherwise stated. To start with, we reported $295.5 million in net revenues for the quarter. For the same quarter last year, we reported net revenues of $191.3 million. Kinpeygo net product sales for the quarter amounted to $278.3 million, worth $26.8 million, which is a reported increase of 50% from the same quarter the previous year. As Renee mentioned, the cyber attack had an estimated negative impact on revenues in the quarter of approximately $4.7 million. This revenue is not lost but will roll forward into the next several months. Therefore, we have updated today on the progress to date for the payer in the second quarter, and we were very encouraged to report that the preliminary survey of net sales in the second quarter to date amounts to $25.5 million, which are almost already at the level at the reported Q1 net sales with approximately 40% of the quarter remaining. The remaining $30 million in revenues for the quarter is related to partnerships primarily from royalties for Europe from Everest Medicines. For the same quarter last year, we had royalty revenues for Europe of $4.4 million. Total operating expenses for the quarter amounted to $485.3 million, compared to $362.4 million for the same quarter last year. The cost for research and development increased by $24 million in the quarter to $150.6 million, compared to $126.7 million for the same quarter last year. And this is primarily related to a pipeline where we just had a positive readout in head and neck and have two more expected data readouts this year, including Setanaxib and Gd-IgA1, which is expected in the third quarter. Moreover, as we had four trials running, including open label extensions and the head and neck, which are close to being completed. Also, from a cost perspective, in the PBS and the open trial, which are running at full speed, the R&D cost between quarters may be somewhat lumpy and less linear this year, but as previously communicated, we expect R&D costs for the year to be broadly in line with the previous year. The cost for sales and marketing increased by 72.9 million, a quarter to quarter, to 240.1 million, compared to 167.2 million for the same quarter the previous year. The increase is primarily related to sales and marketing operations in the US, where we, during the quarter, continued our work to leverage the market opportunity for the full approval we received at the end of last year. These included costs related to completely new marketing materials due to the new indication. And as previously communicated, we started this investment in the commercial organization already in Q4, and we have particularly strengthened the sales, marketing, and market access functions during the first quarter. We reported an operating loss of 203.8 million for the quarter, compared to a loss of 180.1 million for the same quarter last year. The cash flow used in operating activities in the quarter was 198.2 million, compared to 231.9 million for the same quarter last year. And this leaves us with a net decrease in cash in the first quarter of 27.5 million, and we continue to have a healthy cash position of 810.3 million at the end of the quarter. At last, I wanted to bring to your attention that we believe our 2024 total net sales estimate remains unchanged at between 150 to 180 million dollars for the year. That was all for me. Thank you. And now back to you, Renee.

Renee Aguilar Alexander
19:59 - 21:15

Thank you very much. Next page please. There we go. Um, so just some key takeaways for the quarter. As you've heard, this was another record quarter, both in terms of enrollments and new prescribers with 705 new enrollments and 354 new unique prescribers. We have seen an improved product protection of TARPEYO in the form of both orphan exclusivity and patent protection. Uh, with the new patent expiring in 2043, covering TARPEYO and orphan exclusivity in the US for the new indication expiring December 2030. As Maria has shown, there continues to be strong demand for TARPEYO, with this disease-modifying mechanism. Uh, and we believe that the recent set of active data clearly supports its antifibrotic effect. And we are looking forward to and excited about the upcoming readouts in our clinical pipeline related to rare diseases. And finally, our total revenue guidance remains unchanged, reflecting strong growth expectations. Uh, of 150 to 180 million dollars for the year for the entire franchise. And with that, we're happy to take questions.

Operator
21:25 - 21:47

If you wish to ask a question, please dial the pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key six on your telephone keypad. The next question comes from Moira Rycroft from Jefferies. Please go ahead.

Unknown 1
21:48 - 22:20

Good morning. This is your call for Moira. Uh, can you talk about how many new patients you have seen so far in the second quarter, and for the 25.5 million revenue in the second quarter, which day was the cutoff date and was the 4.7 million included in it? And what are some of the additional assumptions and drivers behind the reiterated revenue guidance for 2024? And I'll have a follow-up question.

Renee Aguilar Alexander
22:21 - 23:24

All right. Well, those were four questions. Let me see if I can start with those. Um, so in terms of the actual, uh, figure of 4.7 million, let's start there. So obviously they will be, uh, playing catch-up over the next several months. So it's not something that's necessarily only going to be in Q2. It'll probably be both over Q2 and Q3. Uh, as the quarter hasn't ended, uh, we're not really in a position to be any more precise about, you know, where we might have seen what coming in from the cyber attack. Um, so I think that's going to have to wait until the quarter is actually completed. Um, in terms of the, um, we're not going to report on any other aspects of Q2. Uh, I think we felt that this was a bit of an exception, because obviously the cyber attack was something that was outside of our control. Um, and it was kind of like these technical issues. We wanted to provide some insight into the quarter to date, and that is truly quarter to date. So that is as of the reporting date. Um, and so I think that covered all of the questions.

Unknown 1
23:27 - 23:52

Yeah. Thanks so much for that. Um, then I guess the second question is, um, can you maybe provide some additional color on the phase three open-label extension data for Tapia? Uh, how do the data inform the treatment gap and timing for starting a second course of therapy? Uh, also, are the data consistent with what you're seeing in the real world? But thank you so much. I'll hop back in the queue.

Renee Aguilar Alexander
23:54 - 24:19

Um, the data will be presented at the upcoming International Society of Nephrology meeting. Uh, and I think that as we mentioned in the press release, um, what we've seen is kind of consistent trends and patterns, as we saw in the original phase three trial. Um, so I think that we'll be happy to kind of, um, take more questions or discuss this maybe more at the R&D day when the, when we, when we, uh, cover some of those aspects as well. And where we will be joined by Professor Richard Philipson.

Unknown 2
24:32 - 24:32

Hello.

Operator
24:37 - 24:43

The next question comes from Vandavan from Guggenheim Securities. Please go ahead.

Unknown 3
24:47 - 25:37

Okay, thanks for taking my question. So I just had one other follow-up on the change, the 4.7 million. Just so I understand the dynamics. So those patients have already received the product. It's just a matter of getting the reimbursement now. Um, getting the payment. Uh, there's no risk that they may not end up getting the product. I just want to confirm that if you could. Uh, and then my other question is on, um, just for the prescriber base that you're seeing now, obviously a nice increase in the number of new prescribers. Is there any change that you're seeing now in terms of which sorts of prescribers are, uh, writing for the product, given the broader label? Um, just thinking in terms of academic or um, community-based physicians versus more community-based doctors. So any sort of insights in terms of where the prescriptions are coming from now would be helpful. Thank you.

Renee Aguilar Alexander
25:38 - 25:39

Maria, do you want to take that?

Unknown 2
25:39 - 25:40

Sure.

Renee Aguilar Alexander
25:40 - 25:40

Um, so maybe.

Maria Törnsén
25:40 - 27:20

I'll first address your, uh, first question on Change Health. So Change Health is one of the largest, uh, claims processors in the US. They process approximately one third of US lives. Um, and the way it works is that every single time you have a new claim, as you need to get a new prescription, either a new patient or an existing patient that is going to get another, um, shipment, um, they need, you know, our pharmacy needs to confirm that the patient still has coverage from their insurance. And that is what Change Health is providing through their online, um, system. And as the system was down, um, it created some issues in terms of verifying insurances. Um, I want to reassure you that all patients are still receiving the drug. We didn't lose any patient per se, but, um, it did provide a bit of delay of approximately ten days when we were unable to verify the insurance for the patients. But that's why Rene mentioned earlier that, um, you know, the revenue is not lost, that it is going to come, you know, over the coming months, to catch up on that gap that we experienced in the first quarter. Um, and with regard to your second question, so prescribers, um, you know, we're very happy that we're seeing both new prescribers, but also existing prescribers, you know, prescribing to additional patients. Um, I don't think we've seen any change in terms of academic versus community nephrologists, but we've always had prescriptions coming from both groups. But, um, I guess you can say that, you know, we're both seeing healthy growth in terms of new prescribers, but also in the existing prescribers, uh, identifying additional patients.

Unknown 3
27:24 - 27:25

Okay. Alright, thank you very much.

Unknown 2
27:26 - 27:26

You're welcome.

Operator
27:34 - 27:39

The next question comes from Eagle from the comments. Please go ahead.

Unknown 4
27:42 - 28:05

Hi, this is for you, Gal. Thanks for taking our questions. Uh, I'm just wondering what you're expecting for the updated guidelines. I'm assuming that will broaden the definition of that at-risk population and reflect the updated label language. I'm just curious what you expect will be specifically included. And if you really view that as a sales inflection point, especially with new prescribers.

Renee Aguilar Alexander
28:07 - 29:04

Yes, we are expecting the guidelines to be up for public review at some point in Q3. Uh, and I think that there we have no knowledge of exactly what will be in those guidelines. But what we have heard and what we observe at different conferences and interactions with many colleagues is clearly that there is a general concern that the existing level of 1g/g may not truly reflect the correct patient population defined as being at risk. So, I think there is, in our view, a significant probability that that level may be reduced. To what level? I don't think that we know. But certainly, I think that would obviously just further broaden the target market, as our label does cover patients that are considered to be at risk.

Unknown 4
29:08 - 29:28

Okay. Understood. And then in terms of the European story at this point, I guess we're waiting for some EU commentary. I'm just curious about what the remaining steps are, and if there's any reason to think that the EU might push back on a full approval, or if your expectation is that everything should be smooth sailing from this point on.

Renee Aguilar Alexander
29:29 - 30:10

It is our expectation that the campaign will receive a positive opinion from the EMA. However, as with all regulatory processes, you can never be entirely sure of what's exactly going to happen. But that would certainly be our expectation. And we're hopeful that the EMA will take this up on their agenda in their upcoming meeting. So if that is the case, there is a possibility that there will be a positive opinion fairly shortly. And then obviously there is that kind of 60 to 67 day delay between a positive opinion and the actual formal decision by the European Commission.

Unknown 4
30:13 - 30:14

Got it.

Unknown 2
30:14 - 30:15

Thank you.

Operator
30:29 - 30:35

The next question comes from Annabel Sam from Stifel. Please provide the portion of the transcript you need help with.

Unknown 5
30:38 - 31:52

Hi, everyone, thanks for taking my question. So just following on from the FDA guidelines. Guidelines, um, you did mention that those seem to be the guidelines that are potentially identifying this at-risk population. But you said that it could also include TARPEYO specifically as a potential treatment. Um, do you have any sense as to how they might talk about TARPEYO? Um, um, within these guidelines? And then secondly, I was just curious, you know, we've all been focused on how long patients are staying on treatment, whether it's nine months or above nine months. Um, but is this really the wrong way of thinking about it? Are you now using this nine-month treatment period as a selling point? I guess especially in light of a competitive environment that seems to be evolving with only chronic therapies? Um, uh, available for these patients. So, um, or possible for these patients. So can you just talk about, I guess, how you're using that nine-month treatment period as a possible selling point as opposed to, um, sort of a guideline for treatment?

Renee Aguilar Alexander
31:54 - 33:51

Uh, thanks. So with regards to the critical guidelines. Um, so obviously we are clearly expecting TARPEYO to be part of the guidelines. Um, and I think that the guidelines obviously are based on scientific evidence, which is ranked, um, you know, based on kind of a by third party, really, who provides the author with that kind of ranking. Uh, and so we believe, obviously, that our data is very strong, uh, and that it will be recognized in the guidelines, uh, in terms of the fact that we have, uh, really, you know, in our view, kind of a disease-modifying, uh, immunomodulatory effect on the cells. Um, and so this is something that we would expect to hopefully be reflected in the guidelines, but as to exactly how that treatment paradigm will be expressed and discussed, we don't, at this point in time, uh, have any insights into how that exactly would, uh, would be kind of described, um, in terms of nine months. And I'll have Maria also comment on that. I guess my view is actually that there is a very significant benefit from a patient perspective, which sometimes I think is forgotten in some of these conversations. Uh, we're obviously, you know, the vast majority of patients are actually diagnosed between the ages of 20 and 40. 40% of these patients are female. And for pretty much most, if not all, of these kind of treatments, um, there is an issue in terms of becoming pregnant if you are on any of these chronic treatments. I think that this is actually an extremely important issue for a very large and important part of this patient population. So, yes, I do think that there could be a very substantial benefit, uh, of actually being able to hopefully delay dialysis, keep patients out of dialysis, hopefully, uh, with intermittent treatments, rather than forcing all patients to be kind of in chronic treatment, but from a kind of, you know, sales perspective. Um, Maria, do you have any comments? Um, yes.

Maria Törnsén
33:51 - 34:45

So I would say, um, you know, two things. I mean, uh, first, you know, we know that what our label says is that the recommended, um, duration is nine months of therapy. Um, and that is also what we provide in all of our promotional materials and all of our communications to our field teams. Um, we also know from market research that this is something that patients appreciate. Um, going back to what I mentioned before, this is a lifelong disease, uh, affecting fairly young patients. And we see in market research that patients, um, really appreciate this nine-month course, uh, with extended benefits. Um, and, um, that that is something that they see as a benefit in treating their, um, their disease. So it's definitely something that is appreciated by, by patients, from what we can see, and also something that physicians recognize, um, um, when they, when they prescribe or use it.

Unknown 2
34:48 - 34:48

Great.

Unknown 5
34:48 - 35:03

And just one more follow-up question. The guidelines. Do you have any analogs as to what kind of impact that could have when a drug is specifically included in the guidelines, as opposed to just say, you know, identifying an at-risk population, something that's more general?

Renee Aguilar Alexander
35:05 - 36:01

You know what? I wish I had something off the top of my head that I could provide you with, that is an excellent question. Um, but I don't necessarily have an analogous situation, but I do think, obviously, this is a rare disease, and I think it is something where these nephrologists are not highly specialized in subcategories of nephrology. So it's actually a very, you know, it's quite a feat to be a nephrologist and cover everything that kind of relates to nephrology. So I do think that these guidelines are going to be very impactful, because I do not think that many of the colleagues who are often kind of maybe interviewed or discussed in this kind of setting, that they are very representative in terms of the broader nephrology community. So my guess is the broader nephrology community of nephrologists will very much appreciate and refer to the guidelines to get some insight into how they might treat these patients.

Unknown 5
36:03 - 36:04

Okay. Great. Thank you.

Operator
36:12 - 36:18

The next question comes from Christopher Udy from Seb. Please go ahead.

Unknown 6
36:20 - 37:01

Father, Christopher Udy from Msub. Thanks very much for taking my questions. I just wanted to check in terms of what you can tell us about the rate of conversion. Um, in the quarter from enrollments to actually dispensing medicines. And then I had a question on Setanaxib. Um, what are your thoughts preliminarily for a phase three trial design? Um, when you go to the FDA for an end of phase two meeting, I'm curious about the number of arms. Other comments would be great as well. Thanks.

Renee Aguilar Alexander
37:03 - 38:15

So with regards to setting the next step. Um, I think that obviously we probably would not go to the FDA on our own with regards to any progression on the oncology side. I think our preference would be to, um, use this time right after the clinical data to engage with potential partners, with other interested partners and gain a bit of insight into which way would be the most effective and efficient way to take this forward in oncology, as we don't have any plans to really do that on our own. I also think that if it has an antifibrotic effect, this could very well have or would be expected to have a very similar effect in solid tumors such as pancreatic cancer, etc. So there might be other solid tumors that partners would choose to go into, not necessarily just head and neck cancer. So, I think that this is something that we will interact with a variety of parties, which we have plans to do over the next couple of months. Um, and really, I think on the basis of that, we will jointly decide on what steps we may or may not take in the near term related to oncology.

Unknown 6
38:16 - 38:17

Okay. Thanks. That's clear.

Renee Aguilar Alexander
38:18 - 38:31

Uh, in terms of rate of conversions, we don't really provide any specifics around that. Um, but obviously, I think what we are seeing and we can talk a little bit about the potential market access friction that we're seeing today.

Maria Törnsén
38:31 - 39:34

Yeah. So, I would say the way I would look at it is that we have a very strong demand for TARPEYO. We get a lot of enrollment forms as you've seen from what we've reported today. Um, in the US, patients need to go through the prior authorization process where we verify the benefits and see if their payer will cover TARPEYO. Um, the situation we're in right now is that we have a full approval label. We have a broad label. But as we mentioned, not all of the payers have updated their policies and some of the largest payers, we expect to update their policies mid-year, which is why we have guided that the second half of the year is going to have stronger revenue. So we don't provide specific conversion rates and how quickly a patient converts from an enrollment form to therapy because it depends on the type of insurance they have. But I think the way I would look at it is as a strong demand, which I think is a lead indicator for future growth and future revenue for the brand.

Unknown 6
39:36 - 39:37

All right. Thanks very much.

Operator
39:43 - 39:49

The next question comes from Susanne VanVasu from VLC. Please go ahead.

Unknown 7
39:52 - 40:20

Hi team. Thanks for taking my questions. First of all, can you comment on the operating expenses? How should we think about how those will develop over time for both R&D and SG&A? And perhaps especially with regards to the sales and marketing expenses, what can you clarify? What drove the increase? And, um, how to think about the run rate going forward. And then I have a follow-up question.

Fredrik Johansson
40:21 - 41:21

Yeah, thank you. I'll take that. So starting with the R&D costs, as I said earlier, we expect some lumpiness between the quarters for the costs, but overall for the year, we expect them to be broadly in line with the previous year. And regarding the sales and marketing expenses. What we see now from Q4 to Q1 is, is roughly a 20% increase. And I believe if you think that we have now taken most of our investment, and I believe that the first quarter is representative. So I would think that for the year, you should expect a 15 to 20% increase from the level of last year.

Unknown 7
41:24 - 41:56

Got it. That's very clear. And then maybe a question on the next step. Now, with recent data in oncology signaling a potential antibiotic effect, for the upcoming readouts, can you give some context on what you would like to see there? The interim futility in PBC is probably straightforward, but perhaps you can share some thoughts on the IPF data study design and thereafter the Alpert data. What will be your view?

Renee Aguilar Alexander
41:59 - 43:51

So I think in terms of the PBC, obviously overall, you know, apart from the endpoints and secondary endpoints, we're also looking at things like fibroscan. And that would obviously be another really interesting component of validating this anti-fibrotic effect. So I think there will be quite a lot in the PBC data that will complement what we've seen from the head and neck cancer trial. IPF is obviously a really interesting aspect and as we've reported, we have also seen in the interim readout from the head and neck cancer that this was one of the pathways that was modulated in that smaller group of patients. And I think that would be something very exciting, the drug trial that's being run right now, as you know, is an investigator-led study and it's also run at half the dose of what we're using in our other clinical trials. But clearly, I think any signal that we could get from that in terms of efficacy would be really exciting. Um, and so this is obviously what we're hoping that we can get to see that data around Q4 of this year. We will spend a little bit more time on this, um, clearly in our R&D day. So the whole point, really of the R&D day is to provide a little bit more insight into this. We will take you through all of the various designs in the pipeline. Uh, and I think obviously also talk a little bit more about what we might expect to see or what we would think would be, uh, you know, positive to see. But I think generally in the PBC, um, I would say apart from the usual factors, I think really it's the FibroScan that we're particularly interested in seeing. And I think also really the, the, the possibility of having a statistically significant effect on fatigue, uh, I think is something else that we'd be very excited to see. So I think that those are probably the two main things.

Unknown 7
43:53 - 43:55

Got it. Thank you very much.

Operator
44:01 - 44:07

The next question comes from Johan Amiry from Red Eye. Please go ahead.

Unknown 8
44:07 - 44:42

Taking our questions. Just a few add-ons. Um, you mentioned that one, uh, private insurance P&T committee has made a decision already, and you expect several to follow by mid-year July. Sort of. What can we expect from that? Based on the complete label. Uh, do you expect to see, uh, reimbursement without prior authorization? Sorry.

Renee Aguilar Alexander
44:45 - 44:46

Maria, do you want to take this?

Maria Törnsén
44:46 - 45:44

Um, sure. So, uh, the insurance company referred to is UnitedHealthcare. They cover approximately 13 million US lives. Uh, they made an update to their policy, um, in May, uh, which reflects our new label. Uh, you know, so we have broad inclusion criteria, removal of UPCR criteria, uh, and recognition of the impact on eGFR. So exactly in line with what we expected. Um, I still believe that, uh, therapy will require prior authorization in the majority of cases. That is very typical in the US. Uh, most rare disease, highly specialized drugs have prior authorization in the majority of cases. Um, but I think the anticipated, you know, positive change that we are anticipating is that it will be easier to get that first approval because their policies will be aligned with our label. So, uh, it will still require prior authorization as expected.

Unknown 8
45:47 - 46:12

Great, and you also extended your commercial team and support team, presumably partly to assist with this review and, of course, to work with the specialists. Can you perhaps give us some more detail on what that requires, or what you work with since the team has been in place since February, I believe?

Maria Törnsén
46:13 - 47:08

Yes. Um. Of course. So we, um, made the decision in Q3 last year to expand our field team, um, and, uh, some other types of functions in anticipation of the board's approval. Um, we now have today, uh, 70 rare disease account managers. So these are sales specialists in the field. We have, in addition, um, hired a social scientist. Uh, we have expanded our market access teams. Um, in terms of bringing in-house or field reimbursement managers and our national account managers. And we've also expanded some of our home office functions in marketing to support, um, our field team with materials and also with digital efforts. So in total, we now have approximately 100 people in the field in the US. Um, to support the full approval and, um, the promotion of TARPEYO.

Unknown 8
47:11 - 47:40

Excellent. And finally, from our side, this cyber attack, it seems to have been handled well, even though it was substantial, especially on the healthcare side. Perhaps it can, uh, give some feel for, uh, what measures you take in preparation if something similar were to happen again.

Renee Aguilar Alexander
47:41 - 48:10

So I think obviously this is a third-party provider. And obviously once something like this happens, there are always quite a lot of follow-up activities, particularly on the Change Health side. Um, I mean, we know from kind of, um, they've actually also gone to Congress and had to explain themselves as to what happened there and so forth. So I think on their side, they have certainly announced that they have taken action to try to ensure that this won't happen again. But exactly what those details are, we are not privy to.

Unknown 8
48:14 - 48:25

Yes. And is there something that you have done on your side to perhaps mitigate? Uh, vis-à-vis Change Health or otherwise?

Unknown 2
48:26 - 48:27

There's very little we can do.

Unknown 8
48:27 - 48:27

It's possible.

Renee Aguilar Alexander
48:28 - 48:45

We can't really do anything because it's really kind of biologics that cover our hub. Um, so we can only kind of try and collaborate with them and look at their systems, etc., what they might do. But actually, it's very difficult to do anything as a kind of third party, because obviously this really relates to the situation at Change Health.

Unknown 8
48:46 - 48:48

Yeah. Thank you. Thank you.

Operator
48:56 - 49:03

The next question comes from Rami Katsuta from LSI Capital. Please go ahead.

Unknown 9
49:06 - 49:25

Hi guys, congrats on the progress and thank you for taking my questions as well. I guess perception matters. Do you have any hypotheses as to why you didn't see changes from baseline in tumor size in conjunction? I guess with the PFS and OS benefits? And then did you measure the score for these patients and could those values have influenced the overall results?

Unknown 2
49:26 - 49:28

Richard Philipson. Yeah, sure.

Richard Philipson
49:28 - 51:47

So I think in this kind of setting of what we were evaluating, we were looking at this treatment on top of pembrolizumab. Pembrolizumab itself is not typically a drug that is used to shrink tumors. What you see are the longer-term benefits in terms of progression-free survival and overall survival with pembrolizumab. And what we're seeing when we add an agent on top of that is we're seeing evidence that patients, when they respond, more patients receiving certain agents tend to achieve stable disease. And those responses, when they are achieved, are more durable. So, you know, I think if we were setting up the study, I think, you know, progression-free survival ideally might have been chosen as a primary endpoint. But we also have to approach it from a feasibility point of view and what's reasonable from a sample size calculation point of view. Um, and changes in tumor size are a sensitive way, um, of detecting, um, a clinical effect. So from a sample size point of view, it was a pragmatic decision to use that endpoint, um, to allow a reasonably sized study and a feasible study, but nevertheless, we had sufficient power to detect changes in PFS. And indeed, that's what we did. So, I mean, overall, in summary, what we're seeing is, um, an increase in patients achieving at least stable disease and the durability of those responses being longer in patients who receive certain agents. I don't think there's anything that would indicate we had a score requirement to get into the study. Um, but I don't think there's anything there, um, that would indicate patients responding differently, uh, with respect to their baseline score. What we do see, um, is that when patients receive treatment with a certain agent, we see evidence from various biomarkers, um, and transcriptomic analyses that there is an increase in the immunological activity of the tumor.

Unknown 9
51:50 - 52:00

Got it. That makes sense. And then I guess switching gears a bit, have the baseline characteristics of patients being prescribed the RPO changed at all with the full approval, or is it still too early to tell?

Maria Törnsén
52:02 - 52:46

All right. Um. Uh, well great question. Um, I think, uh, if you look at the patients that we received prior to the full approval, we did receive patients that were below the cutoff of 1.5. Um, so, um, I think we're seeing a broader, you know, it's early, it's early days, but we're definitely seeing a broader group of patients being prescribed. And I think you can see that in the enrollment numbers that we've reported, um, physicians that previously prescribed to one patient may have a second patient now that is eligible for treatment. So we're starting to see the positive signs. I think it's too early to say, you know, um, what the type of patients are and, you know, what the profile looks like? Uh, since we only have a few months of the new label.

Unknown 9
52:49 - 52:51

Sounds good. Thank you very much.

Unknown 2
52:52 - 52:52

Thanks.

Operator
52:56 - 53:02

The next question comes from Eric Hoggard from Carnegie. Please go ahead.

Unknown 2
53:06 - 53:08

Hi there. Uh, thanks.

Unknown 10
53:08 - 54:09

Thanks a lot for taking my questions. And congrats on the progress. I have a couple of questions from my side. The first one may be for Richard regarding the robust head and neck data. So I was just wondering if you have discussed this data with any opinion leaders. And if you're getting any initial feedback on the PFS and OS data, more specifically, the clinically relevant aspects. The two-month extension of the PFS would be helpful to understand. And then also, when can we expect to see the peer-reviewed publication for the data or any presentations at the scientific meetings, and then finally to complete this? I was just wondering if you could update us a bit on the competitive situation. And highlight the key competitive programs in the clinic that we should monitor. Thank you.

Richard Philipson
54:11 - 55:24

Okay, yes. So definitely we've spoken to external experts. And we also have. Very experienced people working with us who have worked in large pharma oncology settings. And I think both from that point of view and from the external expert's point of view, they consider these outcomes, in terms of progression-free survival, impressive. One of the reassuring things that we observed is that the patients who were randomized to placebo and received pembrolizumab behaved in these long-term outcomes, like PFS, exactly as has been seen in other studies. So we know that our control arm behaved in a very expected way. There's nothing unusual about that control arm. So we're seeing an apparent augmentation of benefit when we added an active treatment on top of that. And yes, definitely those outcomes are considered impressive. We will be preparing a publication and we hope to present the data at SMU later this year.

Renee Aguilar Alexander
55:26 - 57:28

Regarding your question on PBC, at this point in time, it is really the dominant area of focus in PBC, with the pepper currently in regulatory review. There is an expectation that both of those candidates may very well achieve approval this year. There are other similar projects in development. I would say that the way we've looked at PBC is not to be an all-comer for PBC. The trial is not designed that way either. It's really stratified for patients with a higher score on the FibroScan. So we have a trial that is specifically targeting a particular kind of patient group. From our perspective, this is really about looking at either those patients who have a more compromised, fibrotic liver disease as seen on a FibroScan, or really looking at these patients in terms of fatigue, which is a really debilitating and very common issue for all of these patients. So I think those are the two components that we really look at complementing with. Um, so you're not positioning ourselves as kind of, uh, you know, kind of directly competing, uh, you know, with the PBC or with Ocaliva for that matter, which is also why in this trial, we've actually allowed patients to come in with both localized as well as diffuse fibrosis, etc.. So, um, so I think that that's really kind of a slightly different, uh, positioning that we have, but those are still the two kind of drugs really what I think is the main focus of, of, for, for, for anyone looking at PBC at the moment.

Unknown 10
57:30 - 57:31

Thank you so much.

Operator
57:37 - 57:43

The next question comes from Asahi from H.C. Wainwright. Please go ahead.

Asahi
57:48 - 58:14

Uh, hey, Renee and the team. Uh, thanks for taking my question. Um, I just had a quick one. Could you guys give us more color? Um, on the launch in China for Kinpeygo. And I believe you still provide the drug as of now. Uh, how that is going to evolve in the upcoming, uh, years or quarters. Uh, regarding that part. Thanks.

Renee Aguilar Alexander
58:16 - 59:05

Yes. So actually it's a little bit early for us to have any feedback really from, from them. And obviously it was launched um, really a week or two ago, really kind of in China. Um, but it is something obviously that we're super excited about. And we are just as curious as you are in terms of, of how that will develop. Um, so the um, but yes, and obviously because China is not a rare disease and it's a much larger patient population. Uh, in terms of supply. You're correct. Um, you know, we are obviously not directly, but through our existing CDMO relationships, uh, we are providing supply also to China. Um, and I don't see that changing, uh, in the near term. Uh, so my expectation would be that in the near term, we would certainly still continue to, uh, to play that role.

Asahi
59:08 - 59:10

Oh, great. Thanks, Renee. I talked to you guys, too.

Renee Aguilar Alexander
59:11 - 59:18

Okay. Thanks a lot. Uh, and I think that was the last question, uh, for this particular session.

Fortsæt til webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Sprog: Dansk12.11.2026, 12.00
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Sprog: Engelsk12.11.2026, 10.00
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Sprog: Dansk11.11.2026, 12.00
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Sprog: Dansk5.11.2026, 08.30
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Sprog: Engelsk3.11.2026, 08.30
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Sprog: Engelsk29.10.2026, 09.30
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Sprog: Dansk22.10.2026, 08.00
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Sprog: Engelsk15.10.2026, 08.00
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Sprog: Engelsk14.10.2026, 11.00
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Sprog: Dansk28.9.2026, 09.00
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Sprog: Dansk25.8.2026, 08.00
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Sprog: Dansk21.8.2026, 12.00
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Sprog: Engelsk14.8.2026, 09.00
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Sprog: Engelsk14.8.2026, 07.30
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Sprog: Engelsk13.8.2026, 08.30
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Sprog: Engelsk12.8.2026, 07.30
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Sprog: Engelsk16.7.2026, 08.00
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Sprog: Dansk6.5.2026, 08.30
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Sprog: Engelsk6.5.2026, 07.30
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Sprog: Engelsk24.4.2026, 07.30
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…